登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《NEJM，6月25日，Hospitalization and Mortality among Black Patients and White Patients with Covid-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-26

  • Hospitalization and Mortality among Black Patients and White Patients with Covid-19

    List of authors.

    Eboni G. Price-Haywood, M.D., M.P.H., Jeffrey Burton, Ph.D., Daniel Fort, Ph.D., and Leonardo Seoane, M.D.

    Abstract

    BACKGROUND

    Many reports on coronavirus disease 2019 (Covid-19) have highlighted age- and sex-related differences in health outcomes. More information is needed about racial and ethnic differences in outcomes from Covid-19.

    METHODS

    In this retrospective cohort study, we analyzed data from patients seen within an integrated-delivery health system (Ochsner Health) in Louisiana between March 1 and April 11, 2020, who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, the virus that causes Covid-19) on qualitative polymerase-chain-reaction assay. The Ochsner Health population is 31% black non-Hispanic and 65% white non-Hispanic. The primary outcomes were hospitalization and in-hospital death.

  • 原文来源：https://www.nejm.org/doi/full/10.1056/NEJMsa2011686
15浏览量
原文链接
相关报告

  • 《MedRxiv，5月25日，Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-26
    • Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study View ORCID ProfileAndrew Ip, View ORCID ProfileDonald A Berry, Eric Hansen, View ORCID ProfileAndre H Goy, Andrew L Pecora, Brittany A Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M Berry, Nicholas S Berry, Shivam Mathura, Ihor S Sawczuk, Noa Biran, View ORCID ProfileRonaldo C Go, Steven Sperber, Julia A Piwoz, Bindu Balani, Cristina Cicogna, Rani Sebti, Jason Zuckerman, Keith M Rose, Lisa Tank, Laurie Jacobs, Jason Korcak, Sarah L Timmapuri, Joseph P Underwood III, Gregory Sugalski, Carol Barsky, Daniel W Varga, Arif Asif, Joseph C Landolfi, View ORCID ProfileStuart L Goldberg doi: https://doi.org/10.1101/2020.05.21.20109207 Abstract Background: Hydroxychloroquine has been touted as a COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has been proposed as a treatment of critically ill patients. Objective: To describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Design: Retrospective observational cohort study of electronic health records Setting: 13-hospital network spanning the state of New Jersey. Participants: Patients hospitalized between March 1, 2020 and April 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2. Follow up was through May 5, 2020. Main Outcomes: The primary outcome was death. Results: Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of hydroxychloroquine and 1473 (59%) received hydroxychloroquine with azithromycin. After adjusting for imbalances via propensity modeling, compared to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83-1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75-1.28]). *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    86浏览量
    原文链接

  • 《JAMA，3月25日，Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-03-26
    • Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China Shaobo Shi, MD1,2,3; Mu Qin, MD4; Bo Shen, MD1,2,3; et alYuli Cai, MD5; Tao Liu, MD1,2,3; Fan Yang, MD6; Wei Gong, MMSC7; Xu Liu, MD, PhD4; Jinjun Liang, MD, PhD1,2,3; Qinyan Zhao, MD, PhD1,2,3; He Huang, MD, PhD1,2,3; Bo Yang, MD, PhD1,2,3; Congxin Huang, MD, PhD1,2,3 Author Affiliations Article Information JAMA Cardiol. Published online March 25, 2020. doi:10.1001/jamacardio.2020.0950 Abstract Importance Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. However, information on cardiac injury in patients affected by COVID-19 is limited. Objective To explore the association between cardiac injury and mortality in patients with COVID-19. Design, Setting, and Participants This cohort study was conducted from January 20, 2020, to February 10, 2020, in a single center at Renmin Hospital of Wuhan University, Wuhan, China; the final date of follow-up was February 15, 2020. All consecutive inpatients with laboratory-confirmed COVID-19 were included in this study.
    102浏览量
    原文链接